Author: Schreiber, Gideon
Title: The Role of Type I Interferons in the Pathogenesis and Treatment of COVID-19 Cord-id: gs65c3fy Document date: 2020_9_30
ID: gs65c3fy
Snippet: Type I interferons (IFN-I) were first discovered over 60 years ago in a classical experiment by Isaacs and Lindenman, who showed that IFN-Is possess antiviral activity. Later, it became one of the first approved protein drugs using heterologous protein expression systems, which allowed its large-scale production. It has been approved, and widely used in a pleiotropy of diseases, including multiple-sclerosis, hepatitis B and C, and some forms of cancer. Preliminary clinical data has supported its
Document: Type I interferons (IFN-I) were first discovered over 60 years ago in a classical experiment by Isaacs and Lindenman, who showed that IFN-Is possess antiviral activity. Later, it became one of the first approved protein drugs using heterologous protein expression systems, which allowed its large-scale production. It has been approved, and widely used in a pleiotropy of diseases, including multiple-sclerosis, hepatitis B and C, and some forms of cancer. Preliminary clinical data has supported its effectiveness against potential pandemic pathogens such as Ebola and SARS. Still, more efficient and specific drugs have taken its place in treating such diseases. The COVID-19 global pandemic has again lifted the status of IFN-Is to become one of the more promising drug candidates, with initial clinical trials showing promising results in reducing the severity and duration of the disease. Although SARS-CoV-2 inhibits the production of IFNβ and thus obstructs the innate immune response to this virus, it is sensitive to the antiviral activity of externally administrated IFN-Is. In this review I discuss the diverse modes of biological actions of IFN-Is and how these are related to biophysical parameters of IFN-I–receptor interaction and cell-type specificity in light of the large variety of binding affinities of the different IFN-I subtypes towards the common interferon receptor. Furthermore, I discuss how these may guide the optimized use IFN-Is in combatting COVID-19.
Search related documents:
Co phrase search for related documents- action mode and adaptive innate: 1, 2, 3, 4, 5, 6, 7
- activation inhibit and acute ards respiratory distress syndrome: 1, 2
- activation inhibit and adaptive immune response: 1, 2
- activation inhibit and adaptive innate: 1, 2
- activation recruitment and acute ards respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8
- activation recruitment and adaptive immune response: 1, 2, 3, 4
- activation recruitment and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14
- activation result and acute ards respiratory distress syndrome: 1, 2
- activation result and acute ards respiratory distress syndrome develop: 1
- activation result and acute kidney injury: 1
- activation result and adaptive immune response: 1, 2, 3
- activation result and adaptive innate: 1, 2, 3, 4, 5
- acute ards respiratory distress syndrome and adaptive immune response: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute ards respiratory distress syndrome and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- acute ards respiratory distress syndrome develop and adaptive immune response: 1
- acute ards respiratory distress syndrome develop and adaptive innate: 1, 2
- acute kidney injury and adaptive immune response: 1, 2
- acute kidney injury and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8
- acute kidney injury and additional response: 1
Co phrase search for related documents, hyperlinks ordered by date